Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial

por Gooderham, Melinda J., Girolomoni, Giampiero, Moore, Julian O., Silverberg, Jonathan I., Bissonnette, Robert, Forman, Seth, Peeva, Elena, Biswas, Pinaki, Valdez, Hernan, Chan, Gary
Publicado 2022